Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world clinical characteristics and outcomes of patients with myelodysplastic syndrome with TP53 mutation

View Full Paper
Ask AI
Bookmark
Share

Authors

LFLaura L. Fernandes

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals TP53 mutation worsens progression-free survival in myelodysplastic syndrome patients, highlighting urgent treatment needs.

Key Points

  • To investigate the clinical characteristics and outcomes of patients with myelodysplastic syndrome who have TP53 mutations.
  • Retrospective observational study using the COTA real-world database
  • Included patients diagnosed with myelodysplastic syndrome and tested for TP53 mutation
  • Evaluated treatment patterns and time-to-event outcomes using Kaplan-Meier method.
  • 193 out of 1,192 patients had TP53 mutations, showing poorer outcomes than those without mutations
  • Patients with TP53 mutation had a median progression-free survival of 6.9 months compared to 14.3 months for TP53 wild type
  • Response rates to first-line therapy were similar between TP53 mutation and wild type patients.

Cite This Study

Laura L. Fernandes (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a2https://doi.org/10.1182/blood-2025-4606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characteristics and prognostic implications of <i>TP53</i> mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  2. 2Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.2025 · 1 citations
  3. 3Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database2025
  4. 4TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends2025
  5. 5Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT2025 · 1 citations